BACH2 and cancer: Regardless, if further validated or even replicated in other large datasets of prospective studies with more clinical similarities (e.g., same type of cancers), a clinical study to investigate the potential use of BACH2 variants in guiding selection of platinum agents (i.e., between cisplatin and carboplatin) to avoid both acute and chronic nephrotoxicity without compromising the platinum’s effectiveness (i.e., radiological response and overall survival) would be a future step.